Joyce James

1.7k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Joyce James is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Joyce James has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Joyce James's work include Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Joyce James is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Joyce James collaborates with scholars based in United States, Japan and New Zealand. Joyce James's co-authors include Robert C. Armstrong, Mark J. Levis, Ruwanthi N. Gunawardane, Patrick P. Zarrinkar, Shripad S. Bhagwat, Michael F. Gardner, Hitesh Patel, Merryl Cramer, Qi Chao and Kelly G. Sprankle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Joyce James

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

2009 474 citations Patrick P. Zarrinkar, Ruwanthi N. Gunawardane et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce James United States	9	821	490	378	127	123	19	1.1k
Hai Lin China	19	621 0.8×	838 1.7×	158 0.4×	37 0.3×	207 1.7×	41	1.1k
Jacqueline M. Greer United States	15	614 0.7×	756 1.5×	151 0.4×	75 0.6×	418 3.4×	33	1.2k
Mika Kontro Finland	13	423 0.5×	505 1.0×	189 0.5×	43 0.3×	156 1.3×	53	903
Jennifer M. Golas United States	14	315 0.4×	405 0.8×	215 0.6×	334 2.6×	192 1.6×	24	893
Kristina Masson Sweden	12	293 0.4×	386 0.8×	118 0.3×	98 0.8×	90 0.7×	14	693
Rosalind H. Gunby Italy	13	267 0.3×	316 0.6×	222 0.6×	42 0.3×	180 1.5×	17	683
Ramesh Jayaraman Singapore	15	253 0.3×	433 0.9×	344 0.9×	114 0.9×	352 2.9×	18	898
Corynn Kasap United States	6	214 0.3×	253 0.5×	151 0.4×	61 0.5×	115 0.9×	12	490
Sujata Chakraborty United States	10	272 0.3×	286 0.6×	146 0.4×	22 0.2×	94 0.8×	17	541
Guobao Zhang United States	9	197 0.2×	305 0.6×	124 0.3×	154 1.2×	102 0.8×	15	594

Countries citing papers authored by Joyce James

Since Specialization

Citations

This map shows the geographic impact of Joyce James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce James more than expected).

Fields of papers citing papers by Joyce James

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce James. The network helps show where Joyce James may publish in the future.

Co-authorship network of co-authors of Joyce James

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce James. A scholar is included among the top collaborators of Joyce James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce James. Joyce James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

James, Joyce, et al.. (2019). Abstract 3078: Tesetaxel, a novel, oral taxane, crosses intact blood-brain barrier (BBB) at therapeutically relevant concentrations. 3078–3078. 2 indexed citations

James, Joyce, et al.. (2016). An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia. Xenobiotica. 47(10). 856–869. 23 indexed citations

Cortes, Jörge E., Hagop M. Kantarjian, James M. Foran, et al.. (2013). Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status. Journal of Clinical Oncology. 31(29). 3681–3687. 278 indexed citations

Li, Jianke, et al.. (2012). Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers. Blood. 120(21). 4327–4327. 5 indexed citations

Cortes, Jörge E., Hagop M. Kantarjian, James M. Foran, et al.. (2012). Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status. Blood. 120(21). 1507–1507. 4 indexed citations

Liu, Gang, Brian T. Campbell, Mark W. Holladay, et al.. (2012). Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases. ACS Medicinal Chemistry Letters. 3(12). 997–1002. 10 indexed citations

Abraham, Sunny, Michael J. Hadd, Lan P. Tran, et al.. (2011). Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(18). 5296–5300. 13 indexed citations

Matthews, David J., et al.. (2011). Abstract 4485: Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR. Cancer Research. 71(8_Supplement). 4485–4485. 4 indexed citations

Zarrinkar, Patrick P., Robert Armstrong, Ruwanthi N. Gunawardane, et al.. (2009). Abstract #1787: Characterization of the biochemical and cellular activity of the second-generation FLT3 inhibitor AC220. Cancer Research. 69. 1787–1787. 1 indexed citations

10.

Reger, Thomas S., Nicholas Stock, Bowei Wang, et al.. (2009). Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists. Bioorganic & Medicinal Chemistry Letters. 20(3). 1173–1176. 7 indexed citations

11.

Venkatraman, Shankar, Alec D. Lebsack, Michael F. Gardner, et al.. (2009). Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3′,5′-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist. Bioorganic & Medicinal Chemistry Letters. 19(19). 5803–5806. 6 indexed citations

12.

Patel, Hitesh, Robert M. Grotzfeld, Andiliy Lai, et al.. (2009). Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(17). 5182–5185. 26 indexed citations

13.

Cortes, Jörge E., James M. Foran, Darejan Ghirdaladze, et al.. (2009). AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.. Blood. 114(22). 636–636. 54 indexed citations

14.

Chao, Qi, Kelly G. Sprankle, Robert M. Grotzfeld, et al.. (2009). Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor. Journal of Medicinal Chemistry. 52(23). 7808–7816. 167 indexed citations

15.

Zarrinkar, Patrick P., Ruwanthi N. Gunawardane, Merryl Cramer, et al.. (2009). AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 114(14). 2984–2992. 474 indexed citations breakdown →

16.

Zarrinkar, Patrick P., Robert C. Armstrong, Ruwanthi N. Gunawardane, et al.. (2008). AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor. Blood. 112(11). 859–859. 1 indexed citations

17.

James, Joyce, Keith W. Pratz, Adam Stine, et al.. (2008). Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3. Blood. 112(11). 2637–2637. 13 indexed citations

18.

Cortes, Jörge E., James M. Foran, Marcel P. Devetten, et al.. (2007). Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.. Blood. 110(11). 1597–1597. 7 indexed citations

19.

Venkatraman, Shankar, Jongwon Lim, Merryl Cramer, et al.. (2005). Influence of acid surrogates toward potency of VLA-4 antagonist. Bioorganic & Medicinal Chemistry Letters. 15(18). 4053–4056. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact